Aug. 28 at 9:28 AM
$TRAW What could send TRAW higher? 🚀
Traws Pharma has a high-risk/high-reward setup around tivoxavir marboxil (TXM), a potential single-dose oral antiviral for seasonal influenza and bird flu.
Key catalysts include MHRA resubmission in Q3 2026, a planned human influenza Challenge study, and efforts to resolve the FDA clinical hold by year-end.
If TXM shows strong efficacy and safety, TRAW could receive a major valuation re-rating. The company also has ratutrelvir (COVID) and emerging antiviral programs.
Key catalysts: 🦠 TXM + 🇬🇧 MHRA + 🇺🇸 FDA + 🧪 Phase 2 data + 💰 potential
$50M milestone financing.
Very speculative, but potentially huge upside if the clinical/regulatory milestones hit.
